Literature DB >> 7881774

Extrapyramidal symptoms with selective serotonin reuptake inhibitors.

D K Arya1.   

Abstract

BACKGROUND: Several case reports in the literature suggest that selective serotonin reuptake inhibitors can produce extrapyramidal symptoms.
METHODS: Computerised literature searches were used to identify reports on extrapyramidal symptoms and serotonin reuptake inhibitors. Subsequently, manual searches were made for articles in which there was any indication of the mechanisms responsible for these extrapyramidal symptoms.
RESULTS: Only a few reports could be identified in which serotonin reuptake inhibitors were implicated in extrapyramidal symptoms in some patients.
CONCLUSIONS: Evidence is discussed from preclinical and clinical studies suggesting the interaction between serotoninergic and dopaminergic neurotransmitter system, as a possible mechanism for production of extrapyramidal symptoms.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7881774     DOI: 10.1192/bjp.165.6.728

Source DB:  PubMed          Journal:  Br J Psychiatry        ISSN: 0007-1250            Impact factor:   9.319


  15 in total

Review 1.  Functional hypothalamic and drug-induced amenorrhea: an overview.

Authors:  A Lania; L Gianotti; I Gagliardi; M Bondanelli; W Vena; M R Ambrosio
Journal:  J Endocrinol Invest       Date:  2019-02-11       Impact factor: 4.256

Review 2.  A risk-benefit assessment of pharmacotherapies for clinical depression in children and adolescents.

Authors:  J Renaud; D Axelson; B Birmaher
Journal:  Drug Saf       Date:  1999-01       Impact factor: 5.606

3.  Chronic escitalopram treatment restores spatial learning, monoamine levels, and hippocampal long-term potentiation in an animal model of depression.

Authors:  V Bhagya; B N Srikumar; T R Raju; B S Shankaranarayana Rao
Journal:  Psychopharmacology (Berl)       Date:  2010-11-04       Impact factor: 4.530

Review 4.  Drug-induced Pisa syndrome (pleurothotonus): epidemiology and management.

Authors:  Toshihito Suzuki; Hisashi Matsuzaka
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

5.  Serotonergic modulation of striatal D2 dopamine receptor binding in humans measured with positron emission tomography.

Authors:  J Tiihonen; M Kuoppamäki; K Någren; J Bergman; E Eronen; E Syvälahti; J Hietala
Journal:  Psychopharmacology (Berl)       Date:  1996-08       Impact factor: 4.530

6.  Chronic 5-HT transporter blockade reduces DA signaling to elicit basal ganglia dysfunction.

Authors:  Emanuela Morelli; Holly Moore; Tahilia J Rebello; Neil Gray; Kelly Steele; Ennio Esposito; Jay A Gingrich; Mark S Ansorge
Journal:  J Neurosci       Date:  2011-11-02       Impact factor: 6.167

7.  Dose-Dependent Effect of Flouxetine on 6-OHDA-Induced Catalepsy in Male Rats: A Possible Involvement of 5-HT1A Receptors.

Authors:  Hamdolah Sharifi; Alireza Mohajjel Nayebia; Safar Farajnia
Journal:  Adv Pharm Bull       Date:  2013-02-07

Review 8.  A new logical insight and putative mechanism behind fluoxetine-induced amenorrhea, hyperprolactinemia and galactorrhea in a case series.

Authors:  Somnath Mondal; Indranil Saha; Saibal Das; Abhrajit Ganguly; Debasis Das; Santanu Kumar Tripathi
Journal:  Ther Adv Psychopharmacol       Date:  2013-12

9.  Rising Trend of Use of Antidepressants Induced Non- Puerperal Lactation: A Case Report.

Authors:  Prerna Kukreti; Wazid Ali; R C Jiloha
Journal:  J Clin Diagn Res       Date:  2016-06-01

10.  A case of galactorrhea associated with excitalopram.

Authors:  Se-Hoon Shim; Yeon-Jeong Lee; Eun-Chan Lee
Journal:  Psychiatry Investig       Date:  2009-07-15       Impact factor: 2.505

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.